Therapeutic drug monitoring of mycophenolic acid and clinical outcomes of lupus nephritis: a systematic review and meta-analysis

Therapeutic drug monitoring of mycophenolic acid and clinical outcomes of lupus nephritis: a systematic review and meta-analysis

Introduction Mycophenolic acid (MPA) is a primary immunosuppressive agent used in the treatment of lupus nephritis (LN). While therapeutic drug monitoring (TDM) of MPA is well established in organ transplantation, its role in LN treatment remains uncertain. Our objective was to review and summarise...

Full description

Saved in:

Bibliographic Details
Main Authors:	Wonngarm Kittanamongkolchai, Yingyos Avihingsanon, Suwasin Udomkarnjananun, Natavudh Townamchai, Leelahavanichkul Asada, Thunyatorn Wuttiputhanun, Nuanjanthip Naiyarakseree, Pajaree Chariyavilaskul
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2024-05-01
Series:	Lupus Science and Medicine
Online Access:	https://lupus.bmj.com/content/11/1/e001093.full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Persistent versus resolved donor-specific antibodies predict 10-year antibody-mediated rejection and kidney transplant outcomes in Thailand
by: Theerachai Thammathiwat, et al.
Published: (2025-07-01)

Urine TWEAK level as a biomarker for early response to treatment in active lupus nephritis: a prospective multicentre study
by: Thitima Benjachat Suttichet, et al.
Published: (2019-12-01)

Cyclophosphamide and mycophenolate mofetil as induction therapy in lupus nephritis
by: Božić-Majstorović Ljubinka, et al.
Published: (2024-01-01)

A Randomized Controlled Study of Efficacy and Safety of Accelerated Versus Standard Hepatitis B Vaccination in Patients With Advanced CKD
by: Jathurong Kittrakulrat, et al.
Published: (2024-04-01)

Therapeutic drug monitoring of mycophenolate mofetil for the treatment of pediatric lupus nephritis: A cross-sectional study
by: Navamani Kirubakaran, et al.
Published: (2022-01-01)

A Rare Case of Severe Skin Reaction to Mycophenolate Mofetil in Systemic Lupus Erythematosus with Lupus Nephritis
by: Rubiya M, et al.
Published: (2025-01-01)

Mycophenolic acid trough level assessment in patients with lupus nephritis; does it make a difference?
by: Ahmed E. Abdulgalil, et al.
Published: (2025-03-01)

Effect of a transtheoretical model-based intervention and motivational interviewing on hyperphosphatemia management via telehealth (TMT program) among hemodialysis patients during the COVID-19 pandemic
by: Arrom Thongsunti, et al.
Published: (2024-11-01)

Cost-Utility Analysis of Mycophenolate Mofetil versus Azathioprine Based Regimens for Maintenance Therapy of Proliferative Lupus Nephritis
by: Robert Nee, et al.
Published: (2015-01-01)

WCN25-1843 MYCOPHENOLATE MOFETIL VS TACROLIMUS IN PURE CLASS V LUPUS NEPHRITIS – A RANDOMISED COMPARATIVE STUDY
by: Sanjana Sharma, et al.
Published: (2025-02-01)

Mycophenolate mofetil versus cyclophosphamide, in combination with prednisolone for lupus nephritis induction treatment: Findings from a prospective observational study
by: Rakhesh LR, et al.
Published: (2025-07-01)

Mycophenolate mofetil vs. cyclophosphamide-based induction regimens for lupus nephritis: outcomes at a tertiary care centre in Lahore, Pakistan
by: Muhammad Ahmed Saeed, et al.
Published: (2024-04-01)

The Efficacy of Induction Treatment with a Cyclophosphamide- or Mycophenolate Mofetil-Based Regimen for Active Lupus Nephritis in Thailand: A Retrospective Cohort Study
by: Panuvich Poungsuwan, et al.
Published: (2025-02-01)

ANCA-Associated Necrotizing Glomerulonephritis Overlapping with Mesangial Proliferative Lupus Nephritis Refractory to Plasmapheresis, Steroid Pulse Therapy, and a Combination of Mycophenolate Mofetil and Rituximab
by: Saika Sharmeen, et al.
Published: (2018-01-01)

Lacticaseibacillus rhamnosus attenuates uremic toxins in patients with nondialysis chronic kidney disease through the anti-inflammatory molecules
by: Asada Leelahavanichkul, et al.
Published: (2025-07-01)

Response to “Impact of Prolonged SARS-CoV-2 Dosing Interval in Hemodialysis Patients”
by: Jathurong Kittrakulrat, et al.
Published: (2024-08-01)

The Evolution of Crescents in Lupus Nephritis
by: Ana Malvar, et al.
Published: (2025-05-01)

WCN24-1455 NOT EVERYTHING IN LUPUS IS LUPUS NEPHRITIS
by: Enrique Fleuvier Morales López, et al.
Published: (2024-04-01)

Gender Differences in the Pathogenesis and Outcome of Lupus and of Lupus Nephritis
by: Julie Schwartzman-Morris, et al.
Published: (2012-01-01)

The Complex Role of Gut Microbiota in Systemic Lupus Erythematosus and Lupus Nephritis: From Pathogenetic Factor to Therapeutic Target
by: Emanuele Parodi, et al.
Published: (2025-02-01)

Prospects for the use of belimumab in lupus nephritis
by: N. L. Kozlovskaya, et al.
Published: (2021-08-01)

Evaluation of Treatment Response in Lupus Nephritis
by: Anca BOBIRCA, et al.
Published: (2021-12-01)

Recent advances in the treatment of lupus nephritis
by: Wan-xing Li, et al.
Published: (2022-08-01)

USE OF RITUXIMAB IN PATIENTS WITH LUPUS NEPHRITIS
by: Anna Vasilyevna Torgashina, et al.
Published: (2010-08-01)

Clinical application of belimumab in lupus nephritis
by: Zhou Han, et al.
Published: (2022-10-01)

The impacts of gender differences on systemic lupus erythematosus and lupus nephritis
by: LI Chun-hong, et al.
Published: (2019-01-01)

Fungal microbiome in gut of systemic lupus erythematosus (SLE)-prone mice (pristane and FCGRIIb deficiency), a possible impact of fungi in lupus.
by: Thanya Cheibchalard, et al.
Published: (2024-01-01)

Effect of tacrolimus with mycophenolate mofetil or cyclophosphamide on the renal response in systemic lupus erythematosus patients
by: Siqin Sun, et al.
Published: (2024-12-01)

Therapeutically targeting proinflammatory type I interferons in systemic lupus erythematosus: efficacy and insufficiency with a specific focus on lupus nephritis
by: Benjamin Lai, et al.
Published: (2024-10-01)

Immune Checkpoint Therapy–Induced Lupus Nephritis
by: Imran Humza Hanif, et al.
Published: (2024-05-01)

Lupus nephritis: What new is in morphological diagnosis?
by: S G Radenska-Lopovok
Published: (2008-08-01)

Lupus Nephritis: 10 questions to think about
by: Enrique Morales, et al.
Published: (2025-02-01)

Chemokines and Chemokine Receptors in the Development of Lupus Nephritis
by: Xiaofeng Liao, et al.
Published: (2016-01-01)

Lupus nephritis and thrombotic microangiopathy: A review
by: Larisa A. Bobrova, et al.
Published: (2024-01-01)

Prediction of prognosis and renal outcome in lupus nephritis
by: Farah Tamirou, et al.
Published: (2020-10-01)

Disseminated Strongyloidiasis in a Patient With Lupus Nephritis
by: Muhammad Abu-Rmaileh, et al.
Published: (2023-09-01)

MicroRNAs Implicated in the Immunopathogenesis of Lupus Nephritis
by: Cristen B. Chafin, et al.
Published: (2013-01-01)

Renal biopsy in lupus nephritis: To do or not to do?
by: Manish Rathi, et al.
Published: (2017-01-01)

Clinical significance of urine hepcidin in lupus nephritis
by: TANG Dai-rong, et al.
Published: (2017-01-01)

B cells and treatment progression in lupus nephritis
by: ZHANG Yue-qi, et al.
Published: (2019-01-01)